ImmuneOnco reports 62% partial response rate in Phase 2 NSCLC trial of IMM2510 + chemo

Instil Bio, Inc.

As of July 1, 2025, 33 patients dosed at 10 mg/kg; 21 efficacy-evaluable patients.
Partial responses in 62% of evaluable: 80% (8/10) squamous NSCLC, 46% (5/11) non-squamous.
No dose-limiting toxicities; only one TRAE leading to drug discontinuation; low-grade irAEs.
ImmuneOnco expects to present full data at a future medical conference.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.